| GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting |
DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the acceptance of a Pharmaceutical Pipeline Presentation at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP) in Arizona, United States from May 27 – 30, where Professor Michael E. Thase, MD, Professor of Psychiatry, Perelman School of Medicine, University of Pennsylvania will present clinical data from a randomized, double-blind, placebo-controlled Phase 2b clinical trial with GH001 in patients with treatment-resistant depression (TRD) (GH001-TRD-201). |
globenewswire.com |
2025-05-15 11:00:00 |
Czytaj oryginał (ang.) |
| GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates |
DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended March 31, 2025, and provided updates on its business. |
globenewswire.com |
2025-05-08 11:00:00 |
Czytaj oryginał (ang.) |
| What Makes GH Research (GHRS) a New Buy Stock |
GH Research (GHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-05-05 17:00:43 |
Czytaj oryginał (ang.) |
| GH Research Reports Full Year 2024 Financial Results and Provides Business Updates |
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025 Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy volunteers is ongoing in the UK Full response to the IND hold on track for submission in mid-2025 Cash, cash equivalents, other financial assets and marketable securities of $182.6 million as of December 31, 2024 Net cash proceeds of an additional $139.8 million from public offering received in February 2025 DUBLIN, Feb. 27, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the year ended December 31, 2024, and provided updates on its business. Business Updates GH001 in Patients with TRD GH001, our proprietary inhalable mebufotenin product candidate, is currently being investigated in a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial in approximately 80 patients with treatment-resistant depression (TRD) (GH001-TRD-201). |
globenewswire.com |
2025-02-27 09:00:00 |
Czytaj oryginał (ang.) |
| GHRS Stock Rallies 55% in a Week: Here's What You Should Know |
GH Research stock soars 55% in a week after the company meets the primary goal in a mid-stage depression study of its lead candidate, GH001. |
zacks.com |
2025-02-06 13:26:08 |
Czytaj oryginał (ang.) |
| GH Research Announces Pricing of $150 Million Public Offering |
DUBLIN, Feb. 05, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the pricing of its previously announced underwritten public offering in the United States of 10,000,000 ordinary shares at a public offering price of $15.00 per share for total gross proceeds of approximately $150 million. All of the ordinary shares are being offered by GH Research PLC. The offering is expected to close on February 6, 2025, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 ordinary shares at the public offering price, less underwriting discounts and commissions. |
globenewswire.com |
2025-02-04 22:52:00 |
Czytaj oryginał (ang.) |
| GH Research Announces Proposed Public Offering |
DUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the commencement of an underwritten public offering in the United States of $150 million of ordinary shares. All of the ordinary shares are to be offered by GH Research PLC. In addition, GH Research PLC intends to grant the underwriters an option to purchase up to an additional $22.5 million of ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. |
globenewswire.com |
2025-02-03 18:03:00 |
Czytaj oryginał (ang.) |
| GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction |
DUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company, today reported the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase 2b clinical trial with GH001, an inhalable mebufotenin product candidate, in patients with treatment-resistant depression (TRD) (GH001-TRD-201). GH Research will host a conference call and live webcast today at 8.00 a.m. EST. To register for the event, please click here. |
globenewswire.com |
2025-02-03 09:00:00 |
Czytaj oryginał (ang.) |
| GH Research to Provide Update on Phase 2b Trial with GH001 in TRD |
DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a conference call and live webcast on Monday, February 3, 2025, at 8.00 a.m. EST to provide an update on data from the randomized, double-blind, placebo-controlled Phase 2b trial of GH001 in treatment-resistant depression (TRD). |
globenewswire.com |
2025-01-31 18:01:00 |
Czytaj oryginał (ang.) |
| GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents |
DUBLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided updates on its business and highlighted key upcoming milestones. |
globenewswire.com |
2025-01-10 09:00:00 |
Czytaj oryginał (ang.) |
| Does GH Research (GHRS) Have the Potential to Rally 225.18% as Wall Street Analysts Expect? |
The mean of analysts' price targets for GH Research (GHRS) points to a 225.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-11-20 12:55:25 |
Czytaj oryginał (ang.) |
| GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates |
DUBLIN, Nov. 14, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2024, and provided updates on its business. |
globenewswire.com |
2024-11-14 09:00:00 |
Czytaj oryginał (ang.) |
| 3 Fast-Growing Stocks Analysts See Doubling in Price |
Comparing and selecting stocks for investment may involve any number of increasingly complex strategies and approaches, but sometimes simpler is better: targeting a stock with significant upside potential at an opportune moment. Certainly, achieving this goal is easier said than done, and there is no guarantee that a company expected to make sizable gains will follow through on that promise. |
marketbeat.com |
2024-11-11 09:16:18 |
Czytaj oryginał (ang.) |
| GH Research (GHRS) Moves to Buy: Rationale Behind the Upgrade |
GH Research (GHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-09-09 17:00:26 |
Czytaj oryginał (ang.) |
| After Plunging -18.19% in 4 Weeks, Here's Why the Trend Might Reverse for GH Research (GHRS) |
GH Research (GHRS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
zacks.com |
2024-09-09 14:35:49 |
Czytaj oryginał (ang.) |
| GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates |
DUBLIN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2024, and provided updates on its business. |
globenewswire.com |
2024-09-03 11:05:00 |
Czytaj oryginał (ang.) |
| GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer |
DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the promotion of Dr. Velichka “Villy” Valcheva, MD, MSc. to Chief Executive Officer of the Company. Dr. Valcheva succeeds PD Dr. med. Theis Terwey, co-founder of GH Research. |
globenewswire.com |
2024-09-03 11:00:00 |
Czytaj oryginał (ang.) |
| 3 Psychedelic Stocks to Ride to the Moon and Beyond |
The value of the psychedelic market is expected to approximately triple over the next few years. While not a large market in absolute terms, that growth potential will create many winning stocks. |
investorplace.com |
2024-07-06 11:21:00 |
Czytaj oryginał (ang.) |
| Recent Price Trend in GH Research (GHRS) is Your Friend, Here's Why |
GH Research (GHRS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. |
zacks.com |
2024-05-13 13:55:45 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict a 166.89% Upside in GH Research (GHRS): Here's What You Should Know |
The average of price targets set by Wall Street analysts indicates a potential upside of 166.9% in GH Research (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-05-10 14:56:18 |
Czytaj oryginał (ang.) |
| GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates |
DUBLIN, Ireland, May 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2024, and provided updates on its business. |
globenewswire.com |
2024-05-03 11:00:00 |
Czytaj oryginał (ang.) |
| How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28% |
The average of price targets set by Wall Street analysts indicates a potential upside of 321.3% in GH Research PLC (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-03-05 12:55:26 |
Czytaj oryginał (ang.) |
| GH Research Reports Full Year 2023 Financial Results and Provides Business Updates |
DUBLIN, Ireland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the year ended December 31, 2023, and provided updates on its business. |
globenewswire.com |
2024-02-29 09:00:00 |
Czytaj oryginał (ang.) |
| GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression |
DUBLIN, Ireland, Jan. 18, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it recently received a communication from the European Patent Office (EPO) that it has been granted a patent with claims directed to mebufotenin (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in treating patients diagnosed with major depressive disorder (MDD) and treatment-resistant forms of MDD, such as treatment-resistant depression (TRD). |
globenewswire.com |
2024-01-18 18:30:00 |
Czytaj oryginał (ang.) |
| Can GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect? |
The average of price targets set by Wall Street analysts indicates a potential upside of 488.7% in GH Research PLC (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-01-16 13:22:38 |
Czytaj oryginał (ang.) |
| GH Research Reports Third Quarter Financial Results and Provides Business Updates |
DUBLIN, Ireland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2023, and provided business updates. |
globenewswire.com |
2023-11-09 18:45:00 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for October 25th |
RKDA, GHRS, GPS, RITM and EXAI have been added to the Zacks Rank #1 (Strong Buy) List on October 25, 2023. |
zacks.com |
2023-10-25 12:16:26 |
Czytaj oryginał (ang.) |
| GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression |
DUBLIN, Ireland, Sept. 29, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided updates and guidance on its clinical development program for GH001, its proprietary inhalable mebufotenin (5-MeO-DMT) product candidate, in treatment-resistant depression (TRD). |
globenewswire.com |
2023-09-29 20:45:00 |
Czytaj oryginał (ang.) |
| GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates |
DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2023 and provided business updates. |
globenewswire.com |
2023-08-23 11:00:00 |
Czytaj oryginał (ang.) |
| The 3 Best Psychedelic Stocks to Buy Now |
Psychedelic stocks have a bright future with 13.5% compound annual growth expected through 2029. That growth will certainly draw in investment funding that seeks to capitalize on growth, as psychedelic drugs quickly become a hot topic in the mental health space. |
investorplace.com |
2023-06-29 12:00:53 |
Czytaj oryginał (ang.) |